Treatment of chronic inflammatory conditions
CA 2065286 C · Owner: Stanford, John L. · Inventors: Rook, Graham A. W.; Stanford, John L.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to the use of antigenic and/or immunoregulatory material derived from Mycobacterium vaccae for use in the manufacture of a therapeutic agent for the treatment of pathological condition (other than tuberculosis, leprosy or rheumatoid arthritis) in a patient in which the patient's IgG shows an abnormally high proportion of agalactosyl IgG or in the treatment of a chronic inflammatory disorder (other than rheumatoid arthritis) caused or accompanied by an abnormally high release by macrophages of interleukin-6 and/or tumour necrosis factor.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 24, 1990 and granted May 16, 2000. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended August 24, 2010.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 24, 2012.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.